Latent Labs, a startup founded by former DeepMind scientist Simon Kohl, has emerged from stealth mode backed by $50 million funding. The company intends to harness AI to revolutionize protein generation and optimization, enabling partnerships with biotech and pharmaceutical sectors. Drawing from the success of DeepMind's AlphaFold, which predicted 200 million protein structures, Latent Labs focuses on computationally creating new therapeutic molecules, thus enhancing drug discovery and development. Kohl's transition from DeepMind highlights the growing trend of applying AI in biological research to tackle complex health challenges.
Latent Labs aims to leverage AI to create programmable biological entities, significantly enhancing protein generation and optimization for biotech and pharmaceutical industries.
The fusion of machine learning with biological data allows for a deeper comprehension of diseases, paving the way for innovative drug designs and synthetic proteins.
Collection
[
|
...
]